Showing results (431-440 of 769) with videos related to
Sort By:
Pageof 77
Annals of Neurology|April 18, 1998
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosisM Filippi, M A Horsfield, H J Adèr, et al.Neurology|June 10, 2010
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN De Stefano, A Giorgio, M Battaglini, et al.Journal of Neurology|December 25, 2012
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosisH Vrenken, M Jenkinson, M A Horsfield, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 23, 2000
Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging studyD J Werring, E T Bullmore, A T Toosy, et al.Brain : a Journal of Neurology|October 26, 2000
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activityR B Banati, J Newcombe, R N Gunn, et al.European Radiology|May 6, 2009
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndromeT Korteweg, M Tintore, B M J Uitdehaag, et al.Neurology|August 24, 2005
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI dataJ Sastre-Garriga, G T Ingle, M Rovaris, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.Pageof 77